摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

己酸,2-乙基-,44-羟基-3,6,9,12,15,18,21,24,27,30,33,36,39,42-十四氧杂四四十碳-1-基酯 | 5973-17-1

中文名称
己酸,2-乙基-,44-羟基-3,6,9,12,15,18,21,24,27,30,33,36,39,42-十四氧杂四四十碳-1-基酯
中文别名
苯酚铵
英文名称
phenol amine
英文别名
Phenol.Ammoniak;azane;phenol
己酸,2-乙基-,44-羟基-3,6,9,12,15,18,21,24,27,30,33,36,39,42-十四氧杂四四十碳-1-基酯化学式
CAS
5973-17-1
化学式
C6H6O*H3N
mdl
——
分子量
111.144
InChiKey
XABJJJZIQNZSIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.14
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    24.1
  • 氢给体数:
    1
  • 氢受体数:
    1

文献信息

  • Process for performing an isolated Pd(II)-mediated oxidation reaction
    申请人:Moeller D. Kevin
    公开号:US20060205959A1
    公开(公告)日:2006-09-14
    There is disclosed a process for performing an isolated Pd(II) mediated oxidation reaction electrochemically. The inventive process is performed on an electrode array device having a plurality of separately addressable electrodes. Preferably, the Pd(II) mediated oxidation is a Wacker reaction. Specifically, there is disclosed a process for conducting an isolated Pd(II) mediated oxidation on a plurality of electrodes, comprising providing an electrode array device having a plurality of electrodes with a conductive electrode surface and a matrix or coating material over the electrodes surfaces; providing a solution bathing the electrode array matrix or coating material and electrode surfaces, wherein the solution comprises a transition metal species and a confining agent; and biasing one or a plurality of electrodes (“selected electrode or electrodes”) with a voltage or current to regenerate the transition metal species required for the isolated Pd(II) mediated oxidation, whereby the confining agent limits diffusion of the transition metal species to a volume surrounding each selected electrode surface.
    所披露的是一种用电化学方法进行隔离的Pd(II)催化的氧化反应的过程。该发明过程是在具有多个独立寻址电极的电极阵列设备上进行的。优选地,Pd(II)催化的氧化是一种Wacker反应。具体来说,所披露的是一种在多个电极上进行的隔离Pd(II)催化的氧化过程,包括提供一个具有多个电极的电极阵列设备,电极具有导电电极表面和覆盖在电极表面的基质或涂层材料;提供一个溶液来浸泡电极阵列基质或涂层材料和电极表面,其中该溶液包含过渡属物种和限制剂;以及偏置一个或多个电极(“选定电极或电极”)以电压或电流再生进行隔离Pd(II)催化的氧化所需的过渡属物种,从而限制剂限制了过渡属物种向包围每个选定电极表面的体积内的扩散。
  • SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
    申请人:Cheng T.W. Peter
    公开号:US20080009534A1
    公开(公告)日:2008-01-10
    Compounds are provided which have the structure of Formula (I): wherein R is hydrogen or C 1 -C 4 alkyl; and each of R 1 and R 2 is independently hydrogen, C 1 -C 4 alkyl, halo or C 1 -C 4 alkoxy, and salts thereof, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.
    提供具有以下结构的化合物(I):其中R为氢或C1-C4烷基;R1和R2中的每一个独立地为氢、C1-C4烷基、卤素或C1-C4甲氧基,以及它们的盐,这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
  • [EN] A PROCESS FOR THE PREPARATION OF ROTIGOTINE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LA ROTIGOTINE
    申请人:FIDIA FARMACEUTICI
    公开号:WO2010035111A1
    公开(公告)日:2010-04-01
    A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid- sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-l-methoxy- naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.
    一种制备罗蒂高定(I)及其药用可接受盐的方法,包括将式6的胺与2-噻吩乙酸氢化合物进行还原胺化反应,并利用溴化氢盐5作为中间体(II)。该方法在工业角度具有优势,因为它允许从光学活性的5,6,7,8-四氢-6-(S)-N-丙基基-1-甲氧基-烯(2)出发,以高对映体纯度获得罗蒂高定,避免使用危险的反应物、需要困难的色谱分离或生成副产物。此外,还披露了两种新的结晶形式。
  • PROCESS FOR THE PREPARATION OF ROTIGOTINE
    申请人:Banfi Aldo
    公开号:US20110230541A1
    公开(公告)日:2011-09-22
    A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.
    一种制备罗蒂高定(I)及其药用可接受盐的方法,包括将式6的胺与2-噻吩乙酸-硼氢化钠复合物进行还原胺化反应,并利用溴化氢盐5作为中间体(II)。该方法在工业角度上具有优势,因为它允许从光学活性的5,6,7,8-四氢-6-(S)-N-丙基基-1-甲氧基-烯(2)出发,以高对映体纯度获得罗蒂高定,避免使用危险的反应物、需要困难的色谱分离或生成副产物。此外,还披露了两种新的结晶形式。
  • Multinuclear half metallocene catalyst and method for preparing syndiotactic polystyrene using the same
    申请人:LG Chem Ltd.
    公开号:EP1777230A1
    公开(公告)日:2007-04-25
    Diclosed is a multinuclear transition metal half metallocene catalyst having a multinuclear half metallocene structure in which a transition metal of groups 3 to 10 on periodic table is connected to a cycloalkandienyl group or its derivative group on a side and also connected to phenol or phenolamine compound having a plurality of binding sites on another side. The metallocene catalyst is useful to produce syndiotatic styrene polymer having superior steroreguality, high melting point and broad molecular weight distribution with high activity together with a small amount of a cocatalyst. Further disclosed is a method for preparing styrene polymers using the same catalyst.
    披露了一种多核过渡属半茂属烯催化剂,其具有多核半茂属烯结构,其中周期表3至10族的过渡属连接到一个环戊二烯基团或其衍生物基团一侧,并且连接到另一侧具有多个结合位点的胺化合物。这种茂属烯催化剂可用于生产具有优越的立体构型、高熔点和宽分子量分布的顺反式苯乙烯聚合物,同时还需要少量的共催化剂。还公开了一种使用相同催化剂制备苯乙烯聚合物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫